You're being asked to fund something you can't fully evaluate.

You're being asked to fund something you can't fully evaluate.

The venture lead believes in it. The team is capable. The market narrative sounds plausible. And you have no clean mechanism to distinguish the ventures that are structurally sound from the ones that will surface a fatal flaw 18 months from now — after the budget is spent.

That is not a failure of your judgment. It is a structural gap in how most organizations fund early-stage ventures.

Here's what the data shows across 129 corporate venture cases: in 77.5% of them, the sprint uncovered a reason the venture could not proceed as originally designed — a priority conflict the organization couldn't resolve, a capability the company didn't have, a market assumption that didn't hold under scrutiny. Only 1 in 4 ventures arrived with a clean thesis and an organizational structure capable of executing it. (THC VAD Pattern Library, 2026)

Read that the other way: when a venture lead walks into a budget meeting with conviction and a business plan, the odds are roughly 3 in 4 that there is a structural problem present that neither the plan nor the conviction will surface.

That problem will surface eventually. The only variable is when — and how much capital is committed before it does.

75% of fatal structural signals appear by Sprint Day 6. The diagnostic window is short. The capital window is not.

A GO verdict gives you independent grounds to fund the next phase. A NO-GO protects the capital. A PIVOT redirects before 18 months of build locks in the wrong direction.

The only outcome that costs you is the one where nobody ran the diagnostic before the build started.